Application of berberine hydrochloride in preparation of medicine used for preventing and/or treating acute hepatic failure

A technology of berberine hydrochloride and acute liver failure, applied in the field of biomedicine

Inactive Publication Date: 2015-04-08
CHINA PHARM UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] So far, there are no records and reports about the prevention and/or treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of berberine hydrochloride in preparation of medicine used for preventing and/or treating acute hepatic failure
  • Application of berberine hydrochloride in preparation of medicine used for preventing and/or treating acute hepatic failure
  • Application of berberine hydrochloride in preparation of medicine used for preventing and/or treating acute hepatic failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1. The protective effect of BBR preventive treatment on the survival rate of mice with acute liver failure

[0056] Methods: Male ICR mice, weighing 22-24 grams, were randomly divided into 3 groups, 7 mice in each group. The three groups were model group, BBR low-dose administration group (5mg / kg) and high-dose administration group (10mg / kg). The administration group was administered by intraperitoneal injection for 3 consecutive days, once a day, and the model group was given the same volume of excipients. One hour after the last administration, animals in each group were intraperitoneally injected with D-GalN 800 mg / kg and LPS 30 μg / kg to establish a model. The survival of mice in each group within 24 h after modeling was recorded.

[0057] Results: The experimental results are shown in Table 1. The survival rate of the mice at 24 hours after modeling was 0 in the model group, while the low-dose and high-dose groups were 28.6% and 71.4% respectively. It can...

Embodiment 2

[0060] Example 2. The protective effect of BBR preventive treatment on liver injury and inflammatory injury in mice with acute liver failure

[0061] Methods: Male ICR mice, weighing 22-24 grams, were randomly divided into 4 groups, 10 in each group. The four groups were normal control group, model group, BBR low-dose administration group (5mg / kg) and high-dose administration group (10mg / kg). The administration group was administered by intraperitoneal injection for 3 consecutive days, once a day, and the other groups were given the same volume of excipients. One hour after the last administration, except for the normal control group, animals in other groups were intraperitoneally injected with D-GalN 800 mg / kg and LPS 30 μg / kg to establish models. The mice were sacrificed 2 hours after modeling, and the same liver tissue was taken from different mice. Total RNA was extracted by the Trizol method, and the expression levels of TNF-α, IL-1β and IL-18 mRNA in the liver of the mi...

Embodiment 3

[0066] Example 3. The inhibitory effect of BBR preventive treatment on the expression of Caspase-1 in the liver of mice with acute liver failure

[0067] Methods: Male ICR mice, weighing 22-24 grams, were randomly divided into 4 groups, 10 in each group. The four groups were normal control group, model group, BBR low-dose administration group (5mg / kg) and high-dose administration group (10mg / kg). The administration group was administered by intraperitoneal injection for 3 consecutive days, once a day, and the other groups were given the same volume of excipients. One hour after the last administration, except for the normal control group, animals in other groups were intraperitoneally injected with D-GalN 800 mg / kg and LPS 30 μg / kg to establish models. The mice were sacrificed 2 hours after modeling, and the liver tissues from different mice were collected from the same part, and the total RNA was extracted by Trizol method, and the expression level of Caspase-1 mRNA in mouse...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of berberine hydrochloride shown as a formula (I) in preparation of a medicine used for preventing and/or treating acute hepatic failure and belongs to the field of biological medicine. According to the invention, the prevention and treatment effects of berberine hydrochloride to acute hepatic failure are inspected by building a D-galactosamine and LPS (lipopolysaccharide)-induced acute hepatic failure mouse animal model; results of experimental analysis in biology, pharmacology and molecular biology show that the effects of obviously reducing transaminase, inhibiting oxidative stress injury and inhibiting release of inflammatory factors can be realized by virtue of administration of berberine hydrochloride, and the death rate of acute hepatic failure mice can be obviously reduced, so that research results of the invention show that berberine hydrochloride can be applied to preparation of the medicine used for preventing and/or treating the acute hepatic failure. The formula (I) is described in the specification.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of berberine hydrochloride in the preparation of medicines for preventing and / or treating acute liver failure. Background technique [0002] Berberine Hydrochloride (BBR), commonly known as berberine, is the main isoquinoline alkaloid in Coptis chinensis, with a content of 5% to 8%, accounting for about 40% of the total alkaloids in Coptis chinensis. Its molecular formula is C 20 h 18 ClNO 4 , the chemical name is 5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolane[5,6-α]quinazine hydrochloride, the structure is as follows (I) the formula: [0003] [0004] Berberine hydrochloride has long been included in the Chinese Pharmacopoeia, and is currently used clinically to treat gastrointestinal diseases caused by bacterial infections. In recent years, a large number of studies have shown that berberine has a variety of biological functions. In addition to traditio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4375A61P1/16
CPCA61K31/4375
Inventor 张玉彬王印行许新新张淼张壮伟赵拯王永辰周翠松殷政李睿岩陈欢
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap